MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 5, 2015, Pages 4782-4790

  Li, Hesheng ^a,b   Sun, Qinglei ^a,b   Han, Bing ^c   Yu, Xingquan ^b   Hu, Baoguang ^b   Hu, Sanyuan ^a  

^a SHANDONG UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

^c DEZHOU UNIVERSITY   (China)

Author keywords

EphA2; Hepatocellular carcinoma; Invasion; Migration; MiR 26b; Proliferation

Indexed keywords

EPHRIN RECEPTOR A2; MICRORNA; MIRN26A MICRORNA, HUMAN;

CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; RECEPTOR, EPHA2;

EID: 84937882615     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. El-Serag HB and Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Gao J, Inagaki Y, Song P, Qu X, Kokudo N and Tang W. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res 2012; 65: 23-30.
3. Kubo S, Takemura S, Sakata C, Urata Y and Uenishi T. Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus. Liver Cancer 2013; 2: 40-46.
4. Iorio MV and Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
6. Morishita A and Masaki T. miRNA in hepatocellular carcinoma. Hepatol Res 2015; 45: 128-141.
7. Li T, Yin J, Yuan L, Wang S, Yang L, Du X and Lu J. Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival. Oncol Rep 2014; 31: 1699-1706.
8. Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, Li Q, Zhang Y, Ding Y, Chen B and Chen L. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One 2014; 9: e88393.
9. Wu SM, Ai HW, Zhang DY, Han XQ, Pan Q, Luo FL and Zhang XL. MiR-141 targets ZEB2 to suppress HCC progression. Tumour Biol 2014; 35: 9993-9997.
10. Wang L, Yao J, Zhang X, Guo B, Le X, Cubberly M, Li Z, Nan K, Song T and Huang C. miRNA-302b suppresses human hepatocellular carcinoma by targeting AKT2. Mol Cancer Res 2014; 12: 190-202.
11. Gao B, Gao K, Li L, Huang Z and Lin L. miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC). Biomed Pharmacother 2014; 68: 143-148.
12. Hou F, Yuan W, Huang J, Qian L, Chen Z, Ge J, Wu S, Chen J, Wang J and Chen Z. Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Med Oncol 2012; 29: 2691-2700.
13. Song W, Ma Y, Wang J, Brantley-Sieders D and Chen J. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res 2014; 74: 2444-2454.
14. Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W, Hou F, Ge J, Zhong M, Tang Y, Xia X and Chen Z. EphA2 promotes epithelial-mesenchymal transition through the Wnt/beta-catenin pathway in gastric cancer cells. Oncogene 2014; 33: 2737-2747.
15. Miyazaki T, Kato H, Fukuchi M, Nakajima M and Kuwano H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 2003; 103: 657-663.
16. Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F, De Filippis L, Mangiola A, Maira G, Anile C, De Bonis P, Reynolds BA, Pasquale EB and Vescovi AL. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 2012; 22: 765-780.
17. Wang W, Lin P, Sun B, Zhang S, Cai W, Han C, Li L, Lu H and Zhao X. Epithelial-mesenchymal transition regulated by EphA2 contributes to vasculogenic mimicry formation of head and neck squamous cell carcinoma. Biomed Res Int 2014; 2014: 803914.
18. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK and Calin GA. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov 2013; 3: 1302-1315.
19. Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M and Sood AK. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 2008; 7: 1098-1103.
20. Cui XD, Lee MJ, Kim JH, Hao PP, Liu L, Yu GR and Kim DG. Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis. Hepatology 2013; 57: 2248-2260.
21. Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, Huang CL and Date H. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer 2012; 76: 431-438.
22. Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS and Chen J. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J Clin Invest 2014; 124: 2037-2049.
23. Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y and Chen J. Eph/ephrin profi ling in human breast cancer reveals signifi cant associations between expression level and clinical outcome. PLoS One 2011; 6: e24426.
24. Kaenel P, Mosimann M and Andres AC. The multifaceted roles of Eph/ephrin signaling in breast cancer. Cell Adh Migr 2012; 6: 138-147.
25. Herath NI, Spanevello MD, Doecke JD, Smith FM, Pouponnot C and Boyd AW. Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. Eur J Cancer 2012; 48: 753-762.
26. Chen P, Huang Y, Zhang B, Wang Q and Bai P. EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells. Oncol Lett 2014; 8: 41-46.
27. Tawadros T, Brown MD, Hart CA and Clarke NW. Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells. Br J Cancer 2012; 107: 1737-1744.
28. Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY and Kim DG. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int J Cancer 2010; 126: 940-949.
29. Yang P, Yuan W, He J, Wang J, Yu L, Jin X, Hu Y, Liao M, Chen Z and Zhang Y. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res 2009; 39: 1169-1177.
30. Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H and Zhang X. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res 2014; 20: 2617-2630.
31. Li R, Yuan W, Mei W, Yang K and Chen Z. MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression. Mol Cell Biochem 2014; 396: 295-305.
32. Aydogdu E, Katchy A, Tsouko E, Lin CY, Haldosen LA, Helguero L and Williams C. MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis 2012; 33: 1502-1511.
33. Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, Cao S and Lin X. Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One 2011; 6: e16264.
34. Liang CC, Park AY and Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2: 329-333.
35. Shen G, Lin Y, Yang X, Zhang J, Xu Z and Jia H. MicroRNA-26b inhibits epithelial-mesenchy mal transition in hepatocellular carcinoma by targeting USP9X. BMC Cancer 2014; 14: 393.
36. Yuan W, Chen Z, Chen Z, Wu S, Guo J, Ge J, Yang P and Huang J. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo. Neoplasma 2012; 59: 105-113.
37. Cao J, Guo T, Dong Q, Zhang J and Li Y. miR-26b is downregulated in human tongue squamous cell carcinoma and regulates cell proliferation and metastasis through a COX-2-dependent mechanism. Oncol Rep 2015; 33: 974-980.
38. Li J, Kong X, Zhang J, Luo Q, Li X and Fang L. MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer. Cancer Cell Int 2013; 13: 7.
39. Fan M, Liu Y, Xia F, Wang Z, Huang Y, Li J, Wang Z and Li X. Increased expression of EphA2 and E-N cadherin switch in primary hepatocellular carcinoma. Tumori 2013; 99: 689-696.
40. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW. Identifi cation of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
41. Tetsu O and McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.